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changes in the systemic immune signature in response to multiple infusions of anti-
PD-1antibody are poorly understood.
Methods: We collected whole blood samples from cancer patients before and after
every cycle anti-PD-1 infusion and isolated PBMCs using Ficoll gradient centrifuga-
tion. PBMCs were stained for mass cytometry analyses, and the data were acquired on a
CyTOF 2 Helios (Fluidigm). We evaluated tumour responses using Response
Evaluation Criteria in Solid Tumours, version 1.1 (RECIST v1.1) by computed tomog-
raphy (CT). In addition, we conducted animal experiments to verify our experimental
results.
Results: We revealed a marked increase in the percentage of CXCR3þCD4þCD8- T
cells in blood from cancer patients after the first pembrolizumab infusion. Intriguingly,
the percentage went down after the second infusion in responding patients.
Interestingly, a continuous high percentage of CXCR3þCD4þCD8- T cells was
observed from patients with progressing disease, while a low percentage with stable dis-
ease or partial response confirmed by conventional flow cytometry. Furthermore,
depletion of CXCR3þ cells abolished the improvement of melanoma by anti-PD-1
treatment in mice.
Conclusions: The dynamic changes in CXCR3þCD4þCD8- T cells in blood could be a
prognostic factor and a continuous high percentage of CXCR3þCD4þCD8- T cells
may reflect resistance to anti-PD-1 therapy.
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Background: Checkpoint inhibitors have reshaped the oncology landscape, but their
success comes at the price of immune related adverse events (irAEs). Although rare,
neurological irAEs are often disabling and in some cases fatal.
Methods: We analyzed the clinical data of all patients who were treated with checkpoint
inhibitors and were subsequently diagnosed with neurological irAEs in our institute
since January 2015. Alternative diagnoses such as progressive disease and infectious
causes were ruled out by MRI and cerebrospinal fluid (CSF) cytology and PCR.
Results: Neurological irAEs were diagnosed in six patients. All patients received anti-
PD1, in two cases combined with ipilimumab. Three patients were diagnosed with
aseptic meningitis, two with encephalitis and one patient with radiculitis. In all cases,
there was a remarkable cerebrospinal fluid (CSF) lymphocytosis (70-99%). All six
patients were treated with high-dose steroids. Subsequent intravenous immunoglobu-
lins were administered in three patients. All patients experienced improvement of neu-
rological symptoms after immunosuppressive treatment, with complete resolution of
symptoms in three patients.
Conclusions: These data illustrate that CSF lymphocytosis is a hallmark of neurological
checkpoint inhibitor toxicity and can be used as a diagnostic aid. Since lymphocytic
pleiocytosis is not pathognomonic for neurological irAEs, alternative explanations for
lymphocytic pleiocytosis such as viral infections should be ruled out. We encourage
clinicians to assess leukocyte differentiation in patients with neurological symptoms
that are treated with immune checkpoint inhibitors.
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Background: Immune checkpoint inhibitors (ICI), both anti CTLA-4 and anti PD-1/
PD-L1 agents, have drastically changed the cancer therapies landscape. However, by
unleashing the host immune system, a new class of immune related adverse events
(irAEs) have emerged. It is still unknown if any biomarker may predict irAEs onset.
Methods: A retrospective series of 130 consecutive patients (pts) treated with anti PD-
1/PD-L1 or anti CTLA-4 agents from Jan 2012 to Dec 2017 was analyzed. IrAEs were
graded according to CTCAE v.4.0. The aim of the study was to evaluate changes in
serum markers in pts with irAEs onset. Wilcoxon’s signed rank test was used to assess
the statistical significance of changes in biomarkers. Gray’s test was used to assess differ-
ences in the cumulative incidence function of irAEs among groups of pts.
Results: Pts with a diagnosis of NSCLC n¼ 64 (49%), melanoma n¼ 55 (42%), kidney
n¼ 9 (7%) and others n¼ 2 (2%) were investigated. Median age was 69 years. Baseline
ECOG PS was 1 in 96% of the pts. ICI represented first line treatment for 27% pts,
second line for 57% and third or further line for the remaining 16%. In detail, 18%
were treated with ipilimumab and 82% with anti PD-1/PD-L1 agents (nivolumab 60%,
pembrolizumab 21%, atezolizumab 1%). Overall, 41 (36% of pts) irAEs occurred, 39%
of those were grade 1, 39% grade 2, 15% grade 3 and 7% grade 4. Among pts who devel-
oped irAEs, 50% (21 pts) required immunosuppressive treatment, 25% (11 pts) needed
hospitalization and 25% (11 pts) required ICI discontinuation. In patients with irAEs,
eosinophilic count increased significantly from the therapy start (p¼ 0.03). Higher
NLR (neutrophil to lymphocytes ratio) was associated with lower risk to develop colitis
or diarrhea (p¼ 0.04). Additionally, absolute lymphocytic count decreased in patients
with irAEs (p¼ 0.07) and monocyte count increased in patients with irAEs (p¼ 0.07)
and endocrine irAE (p¼ 0.06). No statistically significant differences in irAEs incidence
were seen according to age (> or 65 years) or sex. Ipilimumab had higher rates of
irAEs (p¼ 0.03).
Conclusions: These results suggest changes in the white cell subpopulation count in pts
who experience irAEs. Further studies are needed to confirm our findings.
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Background: In the new era of precision medicine, identifying clinical or molecular
factors that predict benefit of immune checkpoint inhibitors is crucial to prevent
patients from autoimmune adverse effects and high cost of such agents.
Methods: We conducted this meta-analysis on the basis of the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-analyses) statement. Two reviews
independently completed a search of PubMed and Web of science to identify relevant
clinical trials. The search was conducted using keywords “nivolumab”,
“pembrolizumab”, “atezolizumab” and “immune checkpoint”. The search was limited
to randomized controlled trails (RCTs) published in English.
Results: Eleven eligible studies, including 5,663 patients, were included in this meta-
analysis. In our analysis, PD-1/PD-L1 inhibitor was associated with a 31% reduction in
the risk of death (HR¼ 0.69; 95%CI, 0.64-0.74; P< 0.00001). In subgroup analysis,
patients got overall survival (OS) benefit from PD-1/PD-L1 inhibitors regardless of
PD-L1 expression, and a dose effect relationship between expression of PD-L1 and OS
benefit from PD-1/PD-L1 inhibitors was observed (Interaction, P< 0.00001). Patients
with smoking history achieved greater OS benefits (HR¼ 0.69, 95% CI 0.61-0.77;
P< 0.00001) than never smoker (HR¼ 0.88, 95% CI 0.70-1.11; P¼ 0.28). Compared
with second or later line treatment, there was better OS benefits in first line treatment
subgroup (Interaction, P¼ 0.02). The OS benefits were similar according to age
(Interaction, P¼ 0.74), sex (Interaction, P¼ 0.43), performance status (Interaction,
P¼ 0.68), central nervous system (CNS) metastasis (Interaction, P¼ 0.59), tumor his-
tology (Interaction, P¼ 0.64) and treatment type (Interaction, P¼ 0.36).
Conclusions: In conclusion, PD-L1 expression, smoking status and line of treatment
were potential biomarkers for PD-1/PD-L1 inhibitors. Besides, patients> 75 years of
age might not get OS benefits from this treatment. These results may improve treat-
ment strategies and patient selection for PD-1/PD-L1 inhibitors.
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